Handelsavisen
prelaunch
Companies Energy 068270.KS
06
068270.KS KRX Oil & Gas Exploration & Production

Celltrion Inc

$185 500,00
Open in Charts → Attach watcher ⌖
KRW
Set alert
LatestCelltrion Q2 net profit surges nearly sixfold on biosimilar strength
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
42,54T KRW
P/E
31,7x
EV / Rev
9,8x
Div yield
0,41 %
Op margin
29,6 %
ROE
7,4 %
Net margin
28,4 %
Debt / equity
0,22
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Celltrion Inc operates in the biotechnology sector, generating revenue through the development and commercialization of biosimilar and biologic products, as indicated by its sector classification industry classification.

Business. Celltrion Inc (068270.KS) is a South Korean company primarily engaged in the exploration and production of oil and gas. The firm operates within the broader energy sector, focusing on upstream activities related to petroleum resources. It is headquartered in South Korea and is listed on the Korea Exchange (KRX). Specific details regarding operating segments or geographic revenue breakdowns are not available.

Classification62 %
SectorEnergy
Business sectorOil & Gas
IndustryOil & Gas Exploration & Production
ActivityExploration & Production
Generated · model-assisted
Sell-side consensus
BUY26 analysts
24 buy2 hold0 sell
Avg 12m price target257 340,86

Analyst recommendations

26 analysts · consensus Buy
Buy24
Hold2
Sell0
12-month price target
257 340,86
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
31,7x
P/E
Analysts
Buy
26 analysts · indicative
Ownership
not yet wired
Profitability
7,4 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

3
  • MARKETSCelltrion Q2 net profit surges nearly sixfold on biosimilar strength2026-07-27
  • MARKETSCelltrion foreign stake rises in H1 on strong earnings and IR push2026-07-07
  • MARKETSCelltrion shares rally on record Q2 sales and margin expansion2026-07-03
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy · THIS SECTOR+0,6 %+3,3 %+0,0 %
    Health Care+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 068270.KS. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    Briefing · model-assisted

    Celltrion Inc (068270.KS) has experienced no material changes in its fundamental profile or market signals as of the latest analysis period. A comprehensive review of 17 key fields, excluding four schema-expansion fields, confirmed that the company’s status remains consistent with prior assessments, indicating a period of stability without significant operational or financial shifts. The absence of material changes is further corroborated by the lack of active watcher signals and a near-zero volume of cross-source dispatches over the past 30 days. Between June 25 and July 15, 2026, only two isolated dispatches were recorded on July 3 and July 7, with no associated sentiment data, suggesting minimal external commentary or market reaction during this window. From a structural perspective, Celltrion continues to be covered by four analysts, while maintaining a lean executive structure with one officer. The company currently holds no index memberships and has no identified top holders, reflecting a static ownership and market classification landscape that has not evolved in the recent reporting cycle. This stability implies that investors should not expect immediate catalysts from recent corporate actions or market sentiment shifts. With no new material developments to drive re-rating or strategic reassessment, the focus for stakeholders remains on the existing analyst coverage and the company’s established operational baseline.

    Signals & dispatch

    peak dispatch · 2026-07-07

    Composite-score breakdown

    Synthesis

    Business

    Celltrion Inc (068270.KS) is a South Korean company primarily engaged in the exploration and production of oil and gas. The firm operates within the broader energy sector, focusing on upstream activities related to petroleum resources. It is headquartered in South Korea and is listed on the Korea Exchange (KRX). Specific details regarding operating segments or geographic revenue breakdowns are not available.

    Classification62 %
    SectorEnergy
    Business sectorOil & Gas
    IndustryOil & Gas Exploration & Production
    ActivityExploration & Production
    AI synthesis
    GENERATED

    Celltrion maintains a conservative capital structure with a debt-to-equity ratio of 0.22 and a current ratio of 1.39, indicating adequate short-term liquidity coverage. The balance sheet shows total assets of 22.3 trillion KRW against total liabilities of 5.1 trillion KRW, resulting in a strong equity base of 17.2 trillion KRW. However, the risk assessment flags medium liquidity risk and notes that net cash is negative after subtracting total debt, primarily due to long-term debt of 3.7 trillion KRW and negligible cash and equivalents of -280 KRW. The company generates substantial free cash flow of 836 billion KRW, which supports its ability to service debt despite the low cash balance.

    Profitability metrics show a return on equity (ROE) of 7.36% and a return on assets (ROA) of 5.67%, reflecting efficient use of capital to generate net income of 1.03 trillion KRW. The company achieves a gross profit of 2.47 trillion KRW on revenue of 4.16 trillion KRW, indicating a gross margin of approximately 59.3%. Operating income stands at 1.15 trillion KRW, demonstrating strong operational leverage. While cohort median comparisons are not provided in the input data, the valuation multiples suggest a premium pricing, with a P/E ratio of 31.71 and an EV/EBITDA of 33.26.

    Revenue concentration and geographic exposure details are not explicitly provided in the segment or geography sections of the input data. The analysis relies on the total revenue figure of 4.16 trillion KRW as the primary indicator of scale. Without specific segment breakdowns, the revenue mix is assumed to be driven by the company's core biotechnology activities as per its industry classification.

    Growth trajectory analysis is limited by the absence of historical period data in the input. The current financial snapshot provides a single-period view of revenue and net income, preventing a year-over-year or quarter-over-quarter trend analysis. The company's ability to sustain growth is inferred from its strong free cash flow generation and positive operating income, but specific growth rates cannot be calculated from the available data.

    Risk factors include medium liquidity risk and low dilution risk, with a key flag noting negative net cash after debt subtraction. The dilution risk is assessed as low, supported by the fact that basic and diluted shares outstanding are identical at 229.3 million shares, indicating no significant in-the-money options or convertible securities impacting the share count. The company's financial stability is further supported by its strong equity position and manageable debt levels.

    Recent events and market sentiment are reflected in the IR observations, which show a mean analyst price target of 257,340.86 KRW, significantly higher than the current market price of 175,200 KRW. The mean recommendation of 1.81 (on a scale where 1 is strong buy) indicates strong bullish sentiment among analysts, with 7 strong buy and 17 buy ratings compared to only 2 hold ratings. This suggests that the market may be undervaluing the company's future prospects relative to its current financial performance.

    Celltrion Inc (068270.KS) has experienced no material changes in its fundamental profile or market signals as of the latest analysis period. A comprehensive review of 17 key fields, excluding four schema-expansion fields, confirmed that the company’s status remains consistent with prior assessments, indicating a period of stability without significant operational or financial shifts. The absence of material changes is further corroborated by the lack of active watcher signals and a near-zero volume of cross-source dispatches over the past 30 days. Between June 25 and July 15, 2026, only two isolated dispatches were recorded on July 3 and July 7, with no associated sentiment data, suggesting minimal external commentary or market reaction during this window. From a structural perspective, Celltrion continues to be covered by four analysts, while maintaining a lean executive structure with one officer. The company currently holds no index memberships and has no identified top holders, reflecting a static ownership and market classification landscape that has not evolved in the recent reporting cycle. This stability implies that investors should not expect immediate catalysts from recent corporate actions or market sentiment shifts. With no new material developments to drive re-rating or strategic reassessment, the focus for stakeholders remains on the existing analyst coverage and the company’s established operational baseline.

    Key takeaways
    • Celltrion exhibits strong profitability with a 59.3% gross margin and 1.03 trillion KRW net income, supported by efficient capital utilization (ROE 7.36%).
    • The company maintains a conservative debt-to-equity ratio of 0.22, but faces medium liquidity risk due to negative net cash after debt subtraction.
    • Analyst sentiment is strongly bullish, with a mean price target of 257,340.86 KRW implying significant upside from the current market price of 175,200 KRW.
    • Dilution risk is low, as evidenced by identical basic and diluted share counts of 229.3 million shares.
    • Valuation multiples are premium, with a P/E of 31.71 and EV/EBITDA of 33.26, reflecting high growth expectations in the biotechnology sector.
    • Free cash flow generation is robust at 836 billion KRW, providing ample liquidity for debt servicing and potential reinvestment.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 4

    Analysts project 45.2% upside to the mean price target of 257,341 KRW based on 26 buy recommendations.

    Net income is forecast to surge 143.6% year-over-year to 1.03 trillion KRW in fiscal 2026.

    Revenue is expected to grow at a 21.8% compound annual rate from 2022 to 2026.

    Free cash flow is projected to increase 105.8% year-over-year to 836.2 billion KRW in 2026.

    BEAR CASE · 3

    Long-term debt is projected to more than double to 3.73 trillion KRW by fiscal 2026.

    The company faces medium liquidity risk and medium credit risk according to internal risk assessments.

    Cash conversion ratio of 0.51 is below the 1.22 median for the Oil & Gas cohort.

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2026-05-06
    Q1 2026 · Quarter highlights

    Revenue KRW 1.14T, +36,0% YoY; Operating income +115,2% YoY.

    RevenueKRW 1.14T+36,0 % YoY
    Operating incomeKRW 317.67B+115,2 % YoY
    Net incomeKRW 346.14B+218,5 % YoY
    Free cash flowKRW 324.93B+177,2 % YoY
    EPS
    Operating cash flowKRW 238.15B+109,9 % YoY
    Financials
    Income statement
    RevenueKRW 1.14T
    Gross profitKRW 685.84B
    Operating incomeKRW 317.67B
    Net incomeKRW 346.14B
    Margins
    Gross margin59.9%
    Operating margin27.7%
    Net margin30.2%
    FCF margin28.4%
    Balance sheet
    Total assetsKRW 23.16T
    Total liabilitiesKRW 5.49T
    Total equityKRW 17.67T
    Cash & equivalentsKRW 1.29T
    Long-term debtKRW 3.85T
    Cash flow
    Operating cash flowKRW 238.15B
    CapEx-KRW 102.33B
    Free cash flowKRW 324.93B
    SBC
    P&L flow · revenue → net income
    Revenue KRW 1.14TOperating costs KRW 827.32BNet income KRW 346.14B
    Highlights
    • Revenue KRW 1.14T, +36,0% YoY
    • Operating income +115,2% YoY
    • Net income +218,5% YoY
    • Free cash flow +177,2% YoY
    • Net margin 30.2%

    Valuation TTM

    Market price
    $185 500,00
    Market cap
    $40.18T
    Enterprise value
    $43.91T
    P/E
    31.7x
    Non-GAAP P/E
    EV / Revenue
    9.8x
    EV / Op income
    33.3x
    EV / OCF
    68.0x
    P / B
    2.3x
    P / Tangible book
    2.3x
    Tangible book
    $17.21T
    Net cash
    -$3.73T
    Current ratio
    1.4
    Debt / equity
    0.2
    ROA
    5.7%
    ROE
    7.4%
    Cash conversion
    51.0%
    CapEx / revenue
    -7.4%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    6 224,82
    Predicted surprise
    -0,08
    Beat probability
    45 %
    Analysts
    26
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    revision ratio -0,00 · as of 2026-07-13 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate6 224,82
    Revenueno estimateno estimate5,32T KRW
    Operating incomeno estimateno estimate1,76T KRW
    Full-year consensus mean (period as reported by source) · consensus in KRW. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution26 analysts
    Strong buy7
    Buy17
    Hold2
    Sell0
    Strong sell0
    12-month price target$257 340,86 · Median $257 142,87
    Low $209 523,82High $304 761,92
    Operating income · consensus1,76T KRW
    EPS surprise
    −28,7 %
    reported vs consensus · miss
    Revenue surprise
    −21,8 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$209 523,82
    Mean$257 340,86
    Median$257 142,87
    High$304 761,92
    Spot$185 500,00
    +38.7 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin29,6 %Best in class
    Net Margin28,4 %Best in class
    ROE7,4 %Below median
    Capex / Rev-7,4 %Below median
    D/E0,22Above median
    Cash Conv0,51Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    • Reference data
    How metrics are computed
    • Price To Earnings
      market_price / (net_income / shares_outstanding_diluted)
    • Return On Equity
      net_income / total_equity
    • Capex To Revenue
      capital_expenditure / revenue
    • Market Cap
      market_price * shares_outstanding_diluted
    • Enterprise Value
      market_cap - net_cash
    • Return On Assets
      net_income / total_assets
    Source documents
    • Celltrion Inc Market data — financials · 2026-07-13
    • Celltrion Inc Market data — analyst estimates · 2026-07-13
    • Celltrion Inc Market data — ESG · 2026-07-13
    • Celltrion Inc — company reference export (2026-07-05) · 2026-07-13

    Ownership & reference

    Leadership

    • Sang Jun Jun LeeSenior Vice President

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    068270.KSCanonical
    KRX · KRW

    Intel & risk

    PredictorBeat prob45 %Surprise-0,08Full forecast →
    peak dispatch · 2026-07-07
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-05-06 04:59 UTCEARNINGSQuarterly results — Q1 2026 Revenue KRW 1144.99B · Net KRW 346.14B
    2026-02-05 07:40 UTCEARNINGSQuarterly results — Q4 2025 Revenue KRW 1330.16B · Net KRW 528.43B
    2026-02-05 07:40 UTCEARNINGSAnnual results — FY 2026 Revenue KRW 4162.50B · Net KRW 1029.61B
    2025-11-14 13:21 UTCEARNINGSQuarterly results — Q3 2025 Revenue KRW 1028.97B · Net KRW 331.35B
    2025-08-06 12:15 UTCEARNINGSQuarterly results — Q2 2025 Revenue KRW 961.46B · Net KRW 61.17B
    2025-05-09 12:12 UTCEARNINGSQuarterly results — Q1 2025 Revenue KRW 841.91B · Net KRW 108.67B
    2025-02-25 21:05 UTCEARNINGSQuarterly results — Q4 2024 Revenue KRW 1063.65B · Net KRW 236.65B
    2025-02-25 21:05 UTCEARNINGSAnnual results — FY 2025 Revenue KRW 3557.30B · Net KRW 422.69B
    2024-11-08 12:11 UTCEARNINGSQuarterly results — Q3 2024 Revenue KRW 881.93B · Net KRW 85.59B
    2024-08-07 07:01 UTCEARNINGSQuarterly results — Q2 2024 Revenue KRW 874.74B · Net KRW 78.01B
    2024-02-29 12:14 UTCEARNINGSAnnual results — FY 2024 Revenue KRW 2176.43B · Net KRW 535.65B
    2023-03-03 12:41 UTCEARNINGSAnnual results — FY 2023 Revenue KRW 2283.97B · Net KRW 537.84B
    2022-02-16 08:48 UTCEARNINGSAnnual results — FY 2022 Revenue KRW 1893.40B · Net KRW 579.46B
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data Premium coverage